Guest guest Posted May 23, 1999 Report Share Posted May 23, 1999 So how do we obtain zinaxin? Any number will be appreciated. thanks--- Quote Link to comment Share on other sites More sharing options...
Guest guest Posted May 23, 1999 Report Share Posted May 23, 1999 Forwarding this information I found on Zinaxin from a newsgroup posting as there has been some interest in it here: <snip> >> Yes, I am that Dr. . It's just that I have been bombarded by >>phone calls, v-mail, e-mail, letters, etc. To a point I can understand >>that. But I've become selective about whom I will answer. Yes, I do >>have experience with Zinaxin--probably now >500 patients over the past >>15-16 months. And yes, It has been very effective and very safe. Its >>active ingredient is an extract of two very specific subtypes of ginger >>root--one found in China, one in India--each with an array of potent >>anti-inflammatory compounds which work synergistically when combined. I >>have seen benefit across the spectrum of musculoskeletal/rheumatic >>problems diagnosed in my office, including several patients with >>psoriatic arthritis--in fact one 70+ yr old patient with psoriatic >>arthritis came back and said that her knee was feeling better on the >>Zinaxin, but then stated that her psoriasis, which she had had since her >>20's had cleared up very significantly since being on it--and she stated >>she'd been thru the whole 9 yards of anti-psoriatic junk, including all >>the messy coal tars, etc. >> It does inhibit formation of COX2 mediated inflammatory >>prostaglandins(PGs), but actually at a step before the " COX2-selective >>NSAIDS. " Whereas Celebrex blocks the enzyme from producing the >>inflammatory PGs, esp. PGE2, Zinaxin inhibits the induction of the enzyme >>itself by inhibiting the cytokines responsible for inducing its >>production--IL1 and TNF-alpha. It also inhibits the enzyme >>5-lipoxygenase, which is responsible for formation of inflammatory >>leukotrienes, and thru its inhibition of IL1 and TNF inhibits production >>of several of the enzymes responsible for breakdown of cartilage. >> There is a lot of info on Zinaxin, and will be much more once the >>studies in progress are published. In the meantime, the proof is in the >>pudding. Clinically it is quite effective and without any significant >>medical side effects or interaction with medicines. It has been very >>pleasing to me to have this completely natural alternative to the NSAIDS, >>which I feel have an unacceptable side effect profile for anything but >>very short term use. > > >He asks that people not send him any email, but that if there are any >questions that needed answering, I could send them to him. <snip> >> How does Zinaxin work as a -2 inhibitor? >> >>Dr. Morton Wiedner who developed Zinaxin (Zinaxin extract is referred to as >>EV.EXT 33) writes, " EV.EXT 33 is a slightly selective COX-2 inhibitor at >>the enzyme level. In addition to this, EV.EXT 33 enhances the secretion of >>IL-4 and IL-10, which selectively inhibits the expression of COX-2 in >>inflammatory cells. This is a new and interesting pharmacological effect, >>which differentiates EV.EXT 33 from the new NSAIDS which are selective >>COX-2 inhibitors only at the enzyme level. The effects on IL-4 and IL-10 >>secretion are also interesting because these interleukins stimulate >>secretion of growth factors that can increase the regeneration of cartilage >>in the joints, thus resulting in a disease modifying effect in >>osteoarthritis. EV.EXT 33 is a strong inhibitor of 5-lipooxygenase, the >>enzyme responsible for the generation of leukotriene B4, which is one of >>the most powerful chemotactic factors involved in chronic inflammation in >>relation to rheumatic disorders. EV.EXT 33 also inhibits leukotriene C4, >>but the role of this leukotriene is not well established in relation to the >>pathogenesis of arthritic conditions. Leukotriene C4 is known for its >>central role in asthma and allergic rhinitis. " >> >>This January 23, 1999, Eurovita introduced an improved " Fast-acting >>Zinaxin " called EV.EXT 77. This new Zinaxin includes the same extract, >>with the addition of another extract from a different one of the 200+ >>subspecies of ginger. Here is a basic outline from Eurovita that explains >>how it works: >> >>Fast-acting Zinaxin inhibits the formation of: >> >>1. Prostoglandins (PGE2) - responsible for acute symptoms >>2. Leukotrienes - responsible for long term aggravation >>3. Cytokins (TNF- and IL-1) - responsible for aggravation and tissue >>destruction >> >>Furthermore, Zinaxin has been shown to stimulate tissue-rebuilding factors: >>Interleukins IL4 and IL 10. >> >>The new Zinaxin is referred to as fast-acting because people feel a >>significant improvement after just five days; Objective clinical findings >>confirm it. >> > >>Studies: >> >>Pilot study, Copenhagen, Denmark by Dr. M. Norgaard >>An open dosefinding study was carried out over three months including 28 >>subjects suffering 735 years from poor joint health. During the first 30 >>days of the study, the subjects were asked to rate themselves on a visual >>analog scale (VAS). In an attempt to minimize bias, subjects were asked to >>send in the VAS every day. Conclusions: >> Good, positive effect (25 out of 28 subjects). >> It is relevant for all people with poor muscle or joint health to try >>Zinaxin. >> No side effects were observed. >> >>Copenhagen Municipal Hospital, Copenhagen, Denmark by Dr. Henning Bliddal >>A group of doctors headed by Dr. Henning Bliddal tested the efficacy and >>safety of the dietary supplement Zinaxin in subjects with unhealthy joints >>in the Copenhagen Municipal area. >>Zinaxin was compared to a placebo in subjects with unhealthy joints of the >>hip or knee in a controlled, double blind, double dummy, crossover study >>with a washout period of one week followed by three treatment periods of >>randomized sequence. Visual analog scale (VAS), Lequesneindex and >>rangeofmotion (ROM) were tested before and at the end of each period, as >>well as measurement of hemoglobin and registration of all adverse events. >>A total of 56 subjects completed the study. A highly significant ranking of >>efficacy of the treatment periods: Zinaxin placebo was found for VAS (chi >>square test 24.65 p) No side effects were observed. >> >>Double blind, double dummy, crossover study, Tan Toc Seng Hospital, >>Singapore by Dr. Leong Keng Hong >>A threeway complete crossover study was performed comparing Zinaxin with >>placebo in subjects with unhealthy knee joints. The treatment period lasted >>three weeks. >>62 subjects completed the study. The average was 59.1 years and 77% of the >>subjects were females. Subjects were measured on a 80mm VAS scale. There >>was an average improvement from placebo to Zinaxin of 2.7mm. This >>difference was significant (p=0.032) on a onetailed Wilcoxon rank sum test. >>These results support findings from a similar study showing that there >>seems to be improvement in the subjects who use Zinaxin for a three week >>period. No adverse events were reported during the study. >> >>Multi-Center, Phase III, Placebo controlled, Double Blind, Block >>Randomized, Two Armed, Five Month Cross-over Study followed by a One Year >>Open Label Phase. United States. [to be released before 2000] To compare >>the efficacy and safety of treatment with oral Zinaxin given twice daily >>over ten weeks versus placebo in subjects with unhealthy knee joints. To >>evaluate the safety and efficacy of Zinaxin in an open label study of one >>year. 140 randomized subjects with a clinical diagnosis of unhealthy knee >>joints, to obtain 100 subjects to evalute. All subjects have been >>randomized into a double-blind phase. >>At each visit, subjects will evaluate their function/mobility according to >>WOMAC. The subjects will give an assessment and global status after >>walking 50 feet, on a visual analog scale (VAS). At the beginning of the >>study, in the middle and at the end of the open label phase, subjects will >>assess their quality of life. >>This study is conducted in accordance with local IRB regulations. Good >>Clinical Practice and the Declaration of Helsinki. >> >>Exciting new studies have shown that Zinaxin inhibits the formation of TNF >>Alpha and IL1 Beta, both of which are involved in poor joint health. >> >>Zinaxin related references from international literature: >> >>Gigtforeningen 1995 (Danish Rheumatism Association) >>Gigtforeningen 1996 (Danish Rheumatism Association)) >>Encyclopedia of Common Natural Ingredients. Ed. LeungAY. WileyInterscience >>1980 >>Teedrogen; Ed. WichtlM 1989 >>Economic and Medicinal Plant Research. Vol.1 >>Ed. WagnerH, HikmoH, New York: Academic Press. 1985:62 >>SrivastavaKC; MustafaT; MedHypotheses. 1989 May, 29(1);258 >>AwangDVC; Herbal Medicine 1992 July; 30911 >>ChenCC; RosenRT; Journal of Chromatography 1986; 360; 16373 >>ChenCC; RosenRT, Journal of Chromatography 1986; 360; 17584 >>SwainAR; DuttonSP; TruswellAS; Journal of The American Dietetic Association >>1985; 85(8); 95060 >>KiuchiF; IwakamiS; ShibuyaM; HanaokaF; SankawaU; ChemPharmBullTokyo. 1992 >>Feb; 40(2); 38791 >>FlynnDL; RaffertyMF; BoctorAM; ProstaglandinsLeukotMed. 1986 Oct; 24(2.3):1958 >>RonneIA; Danish Medical Bulletin 1991 38(4); 291303 >>FoghK; Danish Medical Bulletin 1990 37(4): 289307 >>MascoloN; JainR; JainSC; CapassoJ; JEthnopharmacol. 1989 Nov: 27(12); 12940 >>SrivastavaKC; ProstaglandinsLeukotMed. 1986 Dec: 25(23): 18798 >>YamaharaJ; MochizukiM; RongHQ; Matsuda H; Fujimura H; JEthnopharmacol. 1988 >>JulAug, 23(23): 299304 >>SrivastavaKC; MustafaT; MedHypotheses. 1992 Dec; 29(4): 3428 >>S; RuggierR; HurchinsonSE; Anaesthesia. 1993 Aug; 48(8): 7157 >>GrontvedA; BraskT; KambskardJ; HentzerE; ActaOrolaryngolStockh. 1988 >>JanFeb: 103(12): 459 >>S; HutchinsonS; RuggierR; Anaesthesia. 1993 May; 48(5): 3935 >>HoltmannS; eAH; ScheterH; HohnM; ActaOtolaryngolStockh. 1989 SepOct; >>108(34); 16874 >>FischerRasmussenW; KjaerSK; DahlC; AspingU; EurJObstetGynccolReprodBiol. >>1991 Jan 4: 38(1); 1924 >>JJ; WoodMJ; WoodCD; MimsME; Pharmacology. 1991; 42(2): 11120 >>MowreyDR; ClaysonDE; Lancet. 1982 Mar 20: 1(8273): 6557 > > > Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.